{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:54:28Z","timestamp":1792688068734,"version":"4.5.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T00:00:00Z","timestamp":1723161600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Teprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post-marketing adverse events (AEs). In this study, we aimed to mine and analyze the AEs signals with teprotumumab on the basis of the United States Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) to provide instructions in clinical practice concerning adverse reactions and assistance in drug development and import\/export into other countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>All AE reports were obtained from the FAERS database from the first quarter of 2020 to the fourth quarter of 2023. To comprehensively analyze the AEs, we applied four disproportionality analysis algorithms, including the reporting odds ratio (ROR), the proportional reporting ratio (PRR), the Bayesian confidence propagation neural network (BCPNN), and the multi-item gamma Poisson shrinker (MGPS) algorithms.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 687 reports from 200 patients related to administration of teprotumumab were obtained, and 78% of the cases was female. Signal detection of teprotumumab at the system organ class (SOC) level included gastrointestinal disorders, ear and labyrinth disorders, general disorders and administration site conditions, nervous system disorders, and musculoskeletal and connective tissue disorders. AEs that ranked top five at the preferred terms (PTs) level were muscle spasms, fatigue, tinnitus, headache, and deafness. The median time to those AEs onsets was 48\u00a0days (interquartile range 19.0\u201392.0\u00a0days) after administering drugs. Additionally, our results indicated the AEs in reproductive system and breast disorders because the prevalence of TED was more common in women.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This study identified many AEs associated with teprotumumab and unveiled potential new AE signals. These results can provide valuable evidence for further clinical application of teprotumumab and are important in enhancing clinical medication safety.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2024.1393940","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T04:53:28Z","timestamp":1723179208000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system"],"prefix":"10.3389","volume":"15","author":[{"given":"Jiawei","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1080204","DOI":"10.3389\/fendo.2022.1080204","article-title":"Update on the surgical management of Graves\u2019 orbitopathy","volume":"13","author":"Baeg","year":"2023","journal-title":"Front. Endocrinol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"116116","DOI":"10.1016\/j.envres.2023.116116","article-title":"Emerging roles of air pollution and meteorological factors in autoimmune eye diseases","volume":"231","author":"Cao","year":"2023","journal-title":"Environ. Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1062045","DOI":"10.3389\/fimmu.2023.1062045","article-title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves\u2019 orbitopathy","volume":"14","author":"Cui","year":"","journal-title":"Front. Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1259908","DOI":"10.3389\/fphar.2023.1259908","article-title":"A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?","volume":"14","author":"Cui","year":"","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","article-title":"Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity","volume":"109","author":"Douglas","year":"2024","journal-title":"J. Clin. Endocrinol. & Metabolism"},{"key":"B6","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1097\/WNO.0000000000001134","article-title":"Teprotumumab in clinical practice: recommendations and considerations from the OPTIC trial investigators","volume":"41","author":"Douglas","year":"2021","journal-title":"J. neuro-ophthalmology official J. North American Neuro-Ophthalmology Soc."},{"key":"B8","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s11154-023-09848-8","article-title":"The genetics of Graves\u2019 disease","volume":"25","author":"Grixti","year":"2023","journal-title":"Rev. Endocr. Metabolic Disord."},{"key":"B9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","article-title":"Decision support methods for the detection of adverse events in post-marketing data","volume":"14","author":"Hauben","year":"2009","journal-title":"Drug Discov. Today"},{"key":"B10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of Graves disease and thyroid eye disease","volume":"51","author":"Hoang","year":"2022","journal-title":"Endocrinol. Metabolism Clin. N. Am."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1100397","DOI":"10.3389\/fmed.2023.1100397","article-title":"Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study","volume":"10","author":"Jiang","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled da ta analysis, subgroup analyses, and off-treatment follow-up results fr om two randomised, double-masked, placebo-controlled, multicentre tria ls","volume":"9","author":"Kahaly","year":"2021","journal-title":"lancet. Diabetes & Endocrinol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1136\/bjophthalmol-2015-307399","article-title":"Pathogenesis of thyroid eye disease: review and update on molecular mechanisms","volume":"100","author":"Khong","year":"2016","journal-title":"Br. J. Ophthalmol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"6638089","DOI":"10.1155\/2023\/6638089","article-title":"The efficacy and safety of teprotumumab in thyroid eye disease: evidence from randomized controlled trials","volume":"2023","author":"Lin","year":"2023","journal-title":"Int. J. Clin. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/amiajnl-2012-001119","article-title":"Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records","volume":"20","author":"Liu","year":"2013","journal-title":"J. Am. Med. Inf. Assoc."},{"key":"B16","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1210\/clinem\/dgac606","article-title":"New onset or deterioration of thyroid eye disease after mRNA SARS-CoV-2 vaccines: report of 2 cases and literature review","volume":"108","author":"Mohamed","year":"2023","journal-title":"J. Clin. Endocrinol. & Metabolism"},{"key":"B17","doi-asserted-by":"publisher","first-page":"138","DOI":"10.3390\/life10080138","article-title":"Comparison of data mining methods for the signal detection of adverse drug events with a hierarchical structure in postmarketing surveillance","volume":"10","author":"Park","year":"2020","journal-title":"Life (Basel)"},{"key":"B18","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ajo.2019.07.021","article-title":"A new era in the treatment of thyroid eye disease","volume":"208","author":"Patel","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"109436","DOI":"10.1016\/j.exer.2023.109436","article-title":"Development and application of animal models to study thyroid-associated ophthalmopathy","volume":"230","author":"Shen","year":"2023","journal-title":"Exp. Eye Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1080\/13543784.2020.1772752","article-title":"Teprotumumab: a novel therapeutic monoclonal antibody for thyroid-associated ophthalmopathy","volume":"29","author":"Slentz","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B22","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","article-title":"Graves\u2019 disease","volume":"375","author":"Smith","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/pharmaceutics4040607","article-title":"Signal detection and monitoring based on longitudinal healthcare data","volume":"4","author":"Suling","year":"2012","journal-title":"Pharmaceutics"},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10384-023-01016-4","article-title":"Periocular methotrexate versus periocular triamcinolone injections for active thyroid-associated orbitopathy: a randomized clinical trial","volume":"67","author":"Swaify","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1408135","DOI":"10.3389\/fphar.2024.1408135","article-title":"A real-world disproportionality analysis of Tivozanib data mining of the public version of FDA adverse event reporting system","volume":"15","author":"Wang","year":"","journal-title":"Front. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s12020-024-03852-x","article-title":"An observational study on the safety of teprotumumab based on FAERS database","volume":"85","author":"Wang","year":"","journal-title":"Endocrine"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/j.ophtha.2021.04.024","article-title":"Teprotumumab: interpreting the clinical trials in the context of thyroid eye disease pathogenesis and current therapies","volume":"128","author":"Winn","year":"2021","journal-title":"Ophthalmology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"952954","DOI":"10.3389\/fimmu.2022.952954","article-title":"Research progress on the pathogenesis of Graves\u2019 ophthalmopathy: based on immunity, noncoding RNA and exosomes","volume":"13","author":"Zheng","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1393940\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T04:53:30Z","timestamp":1723179210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1393940\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,9]]},"references-count":31,"alternative-id":["10.3389\/fphar.2024.1393940"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1393940","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,9]]},"article-number":"1393940"}}